# Dexmedetomidine on Postoperative Cognitive Dysfunction and Serum Tau-217 Protein.

> **NCT06366412** · PHASE4 · UNKNOWN · sponsor: **Minia University Hospital** · enrollment: 94 (estimated)

## Conditions studied

- Cognitive Impairment

## Interventions

- **DRUG:** Dexmedetomidine Hydrochloride
- **OTHER:** normal saline

## Key facts

- **NCT ID:** NCT06366412
- **Lead sponsor:** Minia University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04
- **Primary completion:** 2025-03
- **Final completion:** 2026-03
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06366412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06366412, "Dexmedetomidine on Postoperative Cognitive Dysfunction and Serum Tau-217 Protein.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06366412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*